ALBUREX - 5 5 % — DIN 02274655
ALBUMIN (HUMAN) : 5 % · CSL BEHRING CANADA INC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is ALBUREX - 5?
ALBUREX - 5 5 % contains ALBUMIN (HUMAN) : 5 %. It is listed in the Health Canada Drug Product Database under DIN 02274655, held by CSL BEHRING CANADA INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 15-Jan-2008. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ALBUREX - 5 used for?
Restoring and maintaining circulating blood volume; emergency treatment of shock; burns; hypoproteinemia with or without edema.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Albumin cost around the world?
Albumin is listed on 6 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Czechia | max producer price (ex-factory) | 6 | 17 | CZK███.██ |
| Norway | max AUP (pharmacy retail) | 5 | 16 | NOK███.██ |
| Greece | producer price (ex-factory) | 13 | 13 | EUR███.██ |
| Iceland | max wholesale | 5 | 10 | ISK███.██ |
| Bahrain | retail (max) | 1 | 2 | BHD███.██ |
| Hungary | producer price (ex-factory) | 1 | 2 | HUF███.██ |
60 pack listings across 31 brand entries and 5 price bases, refreshed 07 Sep 2026. Ranges span every Albumin pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Albumin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
10 holders have a Canadian DIN containing Albumin, across 20 DINs, of which 5 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| GRIFOLS THERAPEUTICS LLC | 4 | 3 | ALBUMIN (HUMAN) 25% SOLUTION USP, ALBUMIN (HUMAN) 5% SOLUTION, USP, PLASBUMIN-25, PLASBUMIN-5 | Sourceable in Canada |
| CSL BEHRING CANADA INC | 2 | 2 | ALBUREX - 25, ALBUREX - 5 | Sourceable in Canada |
| CUTTER MED & BIOL, DIVISION OF MILES CANADA LTD. | 3 | 0 | NORMAL SERUM ALBUMIN HUMAN 25% USP, PLASBUMIN-5 INJ 50MG/ML, PLASMANATE INJ 0.05GM/ML USP | No marketed DIN |
| BAXTER AG | 2 | 0 | ALBUMIN (HUMAN) 25% SOLUTION, ALBUMIN (HUMAN) 5% SOLUTION | No marketed DIN |
| BAXTER HEALTHCARE CORPORATION | 2 | 0 | BUMINATE 25%, BUMINATE 5% | No marketed DIN |
| GRIFOLS BIOLOGICALS LLC | 2 | 0 | ALBUTEIN 25% SOLN USP, ALBUTEIN 5% SOLN USP | No marketed DIN |
| OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H | 2 | 0 | OCTALBIN 25%, OCTALBIN 5% | No marketed DIN |
| BEHRINGWERKE AG | 1 | 0 | HUMANALBIN INJ 5% | No marketed DIN |
| INSTITUTO GRIFOLS S.A. | 1 | 0 | HUMAN ALBUMIN GRIFOLS 20% | No marketed DIN |
| ZLB BEHRING LLC | 1 | 0 | ALBUMINAR-25 | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 5 % |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | Alburex 5: 250 mL and 500 mL glass bottles. Alburex 25: 50 mL and 100 mL glass bottles. |
| Storage | Not explicitly detailed in provided text (section 11 header present but content missing), though products should be used immediately once stopper is perforated. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Albumin |
|---|---|
| ATC code | B05AA01 |
| AHFS class | 16:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02274655 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2274655 |
| Brand name | ALBUREX - 5 |
| Generic / active ingredient | ALBUMIN (HUMAN) : 5 % |
| Market authorization holder | CSL BEHRING CANADA INC |
| Health Canada schedule | Schedule D |
| ATC code | B05AA01 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B05AA |
| Current status | MARKETED |
| Status date | 15-Jan-2008 |
| Original market date | 2008-01-15 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Intravenous infusion only. Rate should not exceed 5 mL/min (Alburex 5) or 1-2 mL/min (Alburex 25). Dose depends on patient size, severity of illness, and fluid/protein losses.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to human albumin or any ingredient; severe anemia; cardiac failure.
Warnings and precautions
Risk of infectious agent transmission (viruses, vCJD); risk of allergic reactions; avoid hypervolemia; do not dilute with water for injection (risk of hemolysis).
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
5 of 20 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ALBUMIN (HUMAN) 25% SOLUTION USP | 25 % | SOLUTION | GRIFOLS THERAPEUTICS LLC | MARKETED | 02223708 |
| ALBUMIN (HUMAN) 5% SOLUTION, USP | 5 % | SOLUTION | GRIFOLS THERAPEUTICS LLC | MARKETED | 02223694 |
| ALBUREX - 25 | 25 % | SOLUTION | CSL BEHRING CANADA INC | MARKETED | 02274663 |
| PLASBUMIN-5 | 50 MG | SOLUTION | GRIFOLS THERAPEUTICS LLC | MARKETED | 02189100 |
| ALBUMIN (HUMAN) 25% SOLUTION | 25 % | SOLUTION | BAXTER AG | CANCELLED POST MARKET | 00427659 |
| ALBUMIN (HUMAN) 5% SOLUTION | 5 % | SOLUTION | BAXTER AG | CANCELLED POST MARKET | 00427675 |
| ALBUMINAR-25 | 25 G / 100 ML | SOLUTION | ZLB BEHRING LLC | CANCELLED POST MARKET | 00624608 |
| ALBUTEIN 25% SOLN USP | 250 MG | SOLUTION | GRIFOLS BIOLOGICALS LLC | DORMANT | 00779571 |
| ALBUTEIN 5% SOLN USP | 50 MG | SOLUTION | GRIFOLS BIOLOGICALS LLC | DORMANT | 00779563 |
| BUMINATE 25% | 25 % | SOLUTION | BAXTER HEALTHCARE CORPORATION | CANCELLED POST MARKET | 00118303 |
2 · Same class — other molecules in ATC B05AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Albumin | ALBUMIN (HUMAN) 25% SOLUTION · ALBUMIN (HUMAN) 25% SOLUTION USP · ALBUMIN (HUMAN) 5% SOLUTION · ALBUMIN (HUMAN) 5% SOLUTION, USP · ALBUMINAR-25 · ALBUREX - 25 · ALBUREX - 5 · ALBUTEIN 25% SOLN USP · ALBUTEIN 5% SOLN USP · BUMINATE 25% · BUMINATE 5% · HUMAN ALBUMIN GRIFOLS 20% · HUMANALBIN INJ 5% · NORMAL SERUM ALBUMIN HUMAN 25% USP · OCTALBIN 25% · OCTALBIN 5% · PLASBUMIN-25 · PLASBUMIN-5 · PLASBUMIN-5 INJ 50MG/ML · PLASMANATE INJ 0.05GM/ML USP | 20 | 5 | Yes |
| Dextran,Combinations | 10% DEXTRAN 40 IN 0.9% SODIUM CHLORIDE INJECTION · 10% DEXTRAN 40 IN 5% DEXTROSE INJECTION · 6% DEXTRAN 70 IN 0.9% SODIUM CHLORIDE INJECTION · DEXTRAN 6% IN 0.9% SODIUM CHLORIDE INJECTION · DEXTRAN 6% IN 5% DEXTROSE INJECTION · GENTRAN 40 10% DEXTROSE 5% INJ · GENTRAN 40 10% SODIUM CHLORIDE 0.9% INJ · GENTRAN-70 6% & SODIUM CHLORIDE 0.9% INJ · LMD 10% IN 0.9% SODIUM CHLORIDE · LMD 10% IN DEXTROSE 5% · MACRODEX 6% IN DEXTROSE · MACRODEX 6% IN NORMAL SALINE · RHEOMACRODEX 10% IN DEXTROSE · RHEOMACRODEX 10% IN NORMAL SALINE | 14 | 2 | Yes |
| Hydroxyethylstarch | HEXTEND · PENTASPAN · VOLULYTE · VOLUVEN | 4 | 2 | Yes |
| Other Plasma Protein Fractions | PLAS+SD · PLASMA PROTEIN FRACTION (HUMAN) PROTENATE | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B05A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B05AX | Blood Plasma | 1 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ALBUREX - 5 called?
The same molecule, Albumin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Alburex | Latin | Czechia, Iceland, Norway |
| ALBUTEIN | Latin | Czechia, Iceland |
| Albunorm | Latin | Czechia, Norway |
| Albumin Grifols | Latin | Norway |
| Flexbumin | Latin | Czechia, Iceland, Norway |
| Albumin Baxalta | Latin | Iceland, Norway |
| HUMAN ALBUMIN BAXALTA | Latin | Czechia |
| HUMAN ALBUMIN CSL BEHRING | Latin | Czechia |
| HUMAN ALBUMIN OCTAPHARMA | Latin | Bahrain |
| Albuman | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.